Article Excerpt: Digital health technologies (DHTs) have emerged as a promising category of health care interventions that leverage technology to prevent, manage, or treat medical conditions. Over the last few years, the U.S. has witnessed rapid growth in the development, regulation, and adoption of DHTs across different disease areas. Accordingly, notable progress has been made in payment for some types of DHTs. However, significant challenges remain for reimbursement of some categories of DHTs, particularly prescription digital therapeutics (PDTs)—defined as health software that delivers a medical intervention to treat or manage a disease, disorder, condition, or injury. For years, the lack of a clear CMS benefit category for PDTs has historically made establishing coverage and coding structures particularly challenging. As a result, both public and private payer coverage of these products has been limited.
Full Article: https://tinyurl.com/4cd52vd4
Article Source: Duke-Margolis Institute for Health Policy